Welcome to the personalized support of CareConnectPSS®

When you sign up for CareConnectPSS®, you will be introduced to your personal Patient Education Liaison and Case Manager.

Pompe Education

Pompe can be difficult to understand. CareConnectPSS® offers in-person and virtual disease and treatment education for you, your family, and other loved ones.
 

TELL ME MORE

Insurance Coverage

Your CareConnectPSS®  team are experts at navigating the healthcare system and can help you understand your benefit coverage and options.

EXPLAIN THE OPTIONS

Financial Assistance

Your CareConnectPSS®  team can help you learn about other tools and financial resources to help you access treatment.
 

EXPLORE FINANCIAL HELP

REAL LIFE

Hear how John faced his challenges

Learn about his diagnosis journey and how he discovered NEXVIAZYME

“NEXVIAZYME was the next logical step towards helping me to manage my late-onset Pompe disease.”

Amy, Kentucky
Chose NEXVIAZYME

Individual experiences may vary.

“My case manager and Patient Liaison also have a wealth of knowledge.”

Amy, Kentucky
Chose NEXVIAZYME

Individual experiences may vary.

“They're compassionate and they're always there. Always. And they never let us go. Not even one day. If we call and we leave a message for them, they'll return it by that same day.”

Irma, Texas
Chose NEXVIAZYME

Individual experiences may vary.

"NEXVIAZYME came at the right time for me. It made a difference in my life. I'm happy with my decision."

Irma, Texas
Chose NEXVIAZYME

Individual experiences may vary.

"Switching to NEXVIAZYME was a good decision for me. I feel more confident navigating the world around me. And I feel like I can be more present for my family and myself.”

John, North Carolina
Chose NEXVIAZYME

Individual experiences may vary.

Join what’s NEX

Sign up for Pompe news, community support, and more.

You’re not alone

Here's a list of organizations* dedicated to rare diseases and the broader Pompe community.

Acid Maltase Deficiency Association (AMDA)

Promotes public awareness and funds research for acid maltase deficiency, another name for Pompe disease.

Pompe Alliance

Pompe Alliance is an organization dedicated to Pompe education, raising disease awareness, and providing helpful resources.

International Pompe Association

The International Pompe Association (IPA) is a federation of Pompe disease patient groups.

Muscular Dystrophy Association (MDA)

The #1 health nonprofit advancing research, care, and advocacy for people with MD, ALS, and related diseases.

Association for Glycogen Storage Disease (AGSD)

Provides information and support to parents and their children with glycogen storage diseases.

National Organization of Rare Disorders (NORD)

A federation of organizations working together to build a better world for people with rare diseases.

United Pompe Foundation

United Pompe Foundation assists patients and their families with medical costs and expenses that may not be covered by insurance.

Genetic Alliance

A nonprofit health advocacy organization committed to transforming health through genetics.

*The organizations and online resources listed above can provide information and support to patients and families living with Pompe disease through disease education; updates on research, clinical trials, and treatment advances; support groups and counseling; and more. Please note that the websites listed above are maintained by the sponsoring organizations; Sanofi therefore does not control and is not responsible for the content of these websites.

IMPORTANT SAFETY INFORMATION AND INDICATION 

WARNING: SEVERE HYPERSENSITIVITY REACTIONS, INFUSION-ASSOCIATED REACTIONS, and RISK OF ACUTE CARDIORESPIRATORY FAILURE IN SUSCEPTIBLE PATIENTS
Hypersensitivity Reactions Including Anaphylaxis
If you are taking NEXVIAZYME, you should know that severe and potentially life-threatening allergic-type reactions known as anaphylaxis and severe hypersensitivity reactions have occurred during and after NEXVIAZYME treatment.You should seek immediate medical care if signs and symptoms of anaphylaxis or hypersensitivity reactions occur. If such a reaction is severe enough, your doctor may decide to immediately discontinue the infusion and provide immediate medical care. Appropriate medical support measures may be administered during your infusion, and you may require close observation during and after NEXVIAZYME administration.
Infusion-Associated Reactions (IARs)
If you are taking NEXVIAZYME, you should know that severe IARs have occurred during and after NEXVIAZYME treatment. If severe IARs occur during your NEXVIAZYME infusion, your doctor may decide to immediately discontinue the infusion and provide appropriate medical care. If you have an acute underlying illness at the time of NEXVIAZYME infusion you may be at greater risk for IARs. If you have advanced Pompe disease you may have compromised heart and breathing function, which may put you at a higher risk of severe complications from IARs. 
Risk of Acute Cardiorespiratory Failure in Susceptible Patients 
If you are likely to develop fluid volume overload, or have acute underlying breathing problems or compromised heart or breathing function that may require fluid restriction, there may be a risk of worsening of your heart or breathing status during NEXVIAZYME infusion. Your doctor may decide that close observation during NEXVIAZYME administration may be necessary.

WARNINGS AND PRECAUTIONS
Hypersensitivity Reactions Including Anaphylaxis: See Boxed WARNING. Your doctor may decide to give you antihistamine, anti-fever and/or steroid medications before your infusions. Your doctor should consider the risks and benefits of restarting the infusion if you have a severe hypersensitivity reaction (including anaphylaxis) to NEXVIAZYME. If a mild or moderate hypersensitivity reaction occurs, your healthcare provider may slow the infusion rate or temporarily stop the infusion.
Infusion-Associated Reactions (IARs): See Boxed WARNING. Your doctor may decide to give you medications before your infusions to decrease the risk of IARs; however, IARs may still occur after receiving these medications. If mild or moderate IARs occur, your healthcare provider should consider decreasing the infusion rate or temporarily stopping the infusion which may help improve the symptoms.
Risk of Acute Cardiorespiratory Failure in Susceptible Patients: See Boxed WARNING.
ADVERSE REACTIONS
The most common adverse reactions (>5%) were headache, fatigue, diarrhea, nausea, joint pain, dizziness, muscle pain, itching, vomiting, shortness of breath, rash, “pins-and-needles” sensation, and hives.
INDICATION
NEXVIAZYME (avalglucosidase alfa-ngpt) is used for the treatment of patients 1 year of age and older with late-onset Pompe disease [lysosomal acid alpha-glucosidase (GAA) deficiency].
Please see full Prescribing Information for complete details, including Boxed WARNING.

IMPORTANT SAFETY INFORMATION AND INDICATION 

WARNING: SEVERE HYPERSENSITIVITY REACTIONS, INFUSION-ASSOCIATED REACTIONS, and RISK OF ACUTE CARDIORESPIRATORY FAILURE IN SUSCEPTIBLE PATIENTS
Hypersensitivity Reactions Including Anaphylaxis
If you are taking NEXVIAZYME, you should know that severe and potentially life-threatening allergic-type reactions known as anaphylaxis and severe hypersensitivity reactions have occurred during and after NEXVIAZYME treatment.You should seek immediate medical care if signs and symptoms of anaphylaxis or hypersensitivity reactions occur. If such a reaction is severe enough, your doctor may decide to immediately discontinue the infusion and provide immediate medical care. Appropriate medical support measures may be administered during your infusion, and you may require close observation during and after NEXVIAZYME administration.
Infusion-Associated Reactions (IARs)
If you are taking NEXVIAZYME, you should know that severe IARs have occurred during and after NEXVIAZYME treatment. If severe IARs occur during your NEXVIAZYME infusion, your doctor may decide to immediately discontinue the infusion and provide appropriate medical care. If you have an acute underlying illness at the time of NEXVIAZYME infusion you may be at greater risk for IARs. If you have advanced Pompe disease you may have compromised heart and breathing function, which may put you at a higher risk of severe complications from IARs. 
Risk of Acute Cardiorespiratory Failure in Susceptible Patients 
If you are likely to develop fluid volume overload, or have acute underlying breathing problems or compromised heart or breathing function that may require fluid restriction, there may be a risk of worsening of your heart or breathing status during NEXVIAZYME infusion. Your doctor may decide that close observation during NEXVIAZYME administration may be necessary.

WARNINGS AND PRECAUTIONS
Hypersensitivity Reactions Including Anaphylaxis: See Boxed WARNING. Your doctor may decide to give you antihistamine, anti-fever and/or steroid medications before your infusions. Your doctor should consider the risks and benefits of restarting the infusion if you have a severe hypersensitivity reaction (including anaphylaxis) to NEXVIAZYME. If a mild or moderate hypersensitivity reaction occurs, your healthcare provider may slow the infusion rate or temporarily stop the infusion.
Infusion-Associated Reactions (IARs): See Boxed WARNING. Your doctor may decide to give you medications before your infusions to decrease the risk of IARs; however, IARs may still occur after receiving these medications. If mild or moderate IARs occur, your healthcare provider should consider decreasing the infusion rate or temporarily stopping the infusion which may help improve the symptoms.
Risk of Acute Cardiorespiratory Failure in Susceptible Patients: See Boxed WARNING.
ADVERSE REACTIONS
The most common adverse reactions (>5%) were headache, fatigue, diarrhea, nausea, joint pain, dizziness, muscle pain, itching, vomiting, shortness of breath, rash, “pins-and-needles” sensation, and hives.
INDICATION
NEXVIAZYME (avalglucosidase alfa-ngpt) is used for the treatment of patients 1 year of age and older with late-onset Pompe disease [lysosomal acid alpha-glucosidase (GAA) deficiency].
Please see full Prescribing Information for complete details, including Boxed WARNING.